Autor(es)

Navarrete, Josselyn Andrea Yaguana ; Rodriguez, Dunia ; Kanno, Alex Issamu ; Leite, Luciana Cezar de Cerqueira ; Trentini, Monalisa Martins

• Tipo de documento: Artigo Científico
• Fonte: Vaccine; v. 57, p. 7-pg., 2025-05-12.

Resumo

Tuberculosis (TB) remains a major global health issue, with current treatments relying on prolonged multidrug regimens that can reduce patient compliance, and lead to drug resistance. Immunotherapeutic vaccines against Mycobacterium tuberculosis (Mtb) offer a novel approach. We have previously shown that the recombinant BCG expressing LTAK63 adjuvant (rBCG-LTAK63) decreases bacillary load and lung inflammation in Mtb-infected mice. In this work, we further investigated specific immune mechanism induced in mice infected with Mtb and treated with rBCG-LTAK63 in combination with conventional chemotherapy; different routes of administration of rBCG-LTAK63 were evaluated, such as SC, IN, and IV. Immunotherapy with rBCG-LTAK63 induces early innate immune cells migration (predominantly NK cells and monocytes/macrophages) to distinct sites; increased IFN-gamma, TNF-alpha, and IL-17 T cells, FoxP3 expressing regulatory T cells correlating with reduced bacillary load, particularly with IN administration. The findings highlight the potential of rBCG-LTAK63 to complement TB treatment. (AU)

• Processo FAPESP: 17/24832-6 - Desenvolvimento de vacinas baseadas em BCG recombinante: Tuberculose, Pertussis, Pneumococo e Schistosoma
• Beneficiário: Luciana Cezar de Cerqueira Leite
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 19/06454-0 - Avaliação de BCG expressando o adjuvante LTAK63 em um modelo de camundongo humanizado como vacina terapêutica para Tuberculose
• Beneficiário: Monalisa Martins Trentini
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado